Method Article
Recombinant technologies have enabled material designers to create novel artificial proteins with customized functionalities for tissue engineering applications. For example, artificial extracellular matrix proteins can be designed to incorporate structural and biological domains derived from native ECMs. Here, we describe the construction and purification of aECM proteins containing elastin-like repeats.
Recombinant technology is a versatile platform to create novel artificial proteins with tunable properties. For the last decade, many artificial proteins that have incorporated functional domains derived from nature (or created de novo) have been reported. In particular, artificial extracellular matrix (aECM) proteins have been developed; these aECM proteins consist of biological domains taken from fibronectin, laminins and collagens and are combined with structural domains including elastin-like repeats, silk and collagen repeats. To date, aECM proteins have been widely investigated for applications in tissue engineering and wound repair. Recently, Tjin and coworkers developed integrin-specific aECM proteins designed for promoting human skin keratinocyte attachment and propagation. In their work, the aECM proteins incorporate cell binding domains taken from fibronectin, laminin-5 and collagen IV, as well as flanking elastin-like repeats. They demonstrated that the aECM proteins developed in their work were promising candidates for use as substrates in artificial skin. Here, we outline the design and construction of such aECM proteins as well as their purification process using the thermo-responsive characteristics of elastin.
For several decades, both synthetic and natural materials have been explored for use as scaffolds in tissue engineering1,2. While synthetic materials such as polymers offer excellent structural integrity and tunable mechanical properties, they often have insufficient bioactivity to promote growth and infiltration of tissues. On the other hand, natural materials such as extracellular matrix (ECM) proteins have excellent biological activity, but have limitations such as batch-to-batch variability, rapid degradation and immunogenicity issues. As such, recombinant proteins are desired, since they can be designed to mimic only the desirable properties of native proteins3,4.
Recombinant protein engineering has garnered widespread interests as a versatile platform for the design and production of novel artificial protein biopolymers. By controlling the genetic sequence, the functionalities of the artificial proteins can be tailored for a wide variety of applications5,6. In particular, artificial extracellular matrix (aECM) proteins can be tailored to have multiple functionalities for applications in tissue engineering, regeneration and wound repair2,7. More importantly, advances in cloning and purification technologies have increased scalability and reduced the cost of manufacturing recombinant proteins tremendously. It is possible to produce large quantities of recombinant proteins at low production costs which are economic for use in the clinic5.
Artificial extracellular matrix proteins have been developed for tissue engineering applications8-11. For instance, Tirrell et al. designed a small diameter vascular graft using artificial proteins containing fibronectin CS5 sequence and elastin-like repeats (ELP-CS5). They showed that human umbilical vein endothelial cells (HUVECs) were able to adhere and grow on these materials12. Others have also incorporated short bioactive sequences taken from fibronectin, collagen, laminin, fibrinogen and vitronectin as well as structural domains that mimic elastin, spider silk and collagens to create a variety of fusion proteins10. Bulk cross-linked films made out of elastin-based aECM proteins also exhibited mechanical properties similar to that of native elastin (elastic moduli ranges between 0.3-0.6 MPa)13. Subsequently, aECM proteins containing longer fibronectin fragments were also reported to accelerate wound healing in vitro due to increased integrin binding affinities8.
Recently, integrin-specific artificial ECM proteins have been developed by Tjin and coworkers14. Each aECM protein contains a bioactive cell-binding domain taken from ECM components of native human skin2,7,15, such as laminin-5, collagen-IV and fibronectin. For example, the integrin α3Β1 has been shown to bind the PPFLMLLKGSTR sequence found in the laminin-5 alpha-3 chain globular domain 3 (LG3)16,17. In their report, they showed that primary human skin epidermal keratinocytes preferentially engage different integrins for binding to each of the aECM proteins, depending on the type of cell binding domain present.
The aECM proteins discussed in the work by Tjin et al. contain flanking elastin-like domains {(VPGIG)2VPGKG(VPGIG)2}8 that confer elasticity which mimics the mechanical properties of human skin. In addition, the incorporation of lysine residues within the elastin-like repeats also increases the overall protein solubility in aqueous solvents. In addition, the lysine residues also serve as crosslinking sites to facilitate the formation of crosslinked aECM films12. Inclusion of elastin-like repeats within the aECM protein sequence allow the proteins to be readily purified via Inverse Transition Cycling (ITC)14. Elastins undergo a sharp and reversible phase transition at a specific temperature known as the lower critical solution temperature (LCST) or the inverse transition temperature (Tt)18-20. Elastins and elastin-like repeats adopt hydrophilic random coil conformations below their LCST and become soluble in water, whereas above their LCST, elastins aggregate rapidly into micron-size particles. Such phase transitions are reversible and hence, can be exploited to allow elastin-based aECM proteins to be readily purified via the ITC technique21.
In this work, we report a generalized procedure to design, construct and purify artificial ECM proteins containing bioactive cell-binding domains, fused to elastin-like repeats. The process to design and clone the plasmids that encode for the amino acid sequences for the aECM proteins is described. The steps involved to purify the aECM proteins using ITC are outlined. Finally, the methods to determine the purity of the aECM proteins obtained using SDS-PAGE electrophoresis and Western Blotting are discussed.
1. Cloning of Recombinant Plasmids Encoding for aECM Proteins
2. Transformation of Recombinant Plasmid into Bacterial Expression Host
3. Bacterial Expression of aECM Proteins
4. Lysis of Bacterial Cultures
5. Purification of aECM Proteins Using Inverse Transition Cycling
6. Characterization of aECM Proteins Using SDS-PAGE Electrophoresis
7. Characterization of aECM Proteins Using Western Blotting
In designing fusion proteins containing elastin-like repeats, it is important to maintain an overall elastin content, large enough fraction of the fusion protein18. This is to ensure that the fusion protein construct retains its elastin-like characteristics, in order to use ITC for purification. The aECM proteins design and sequences described in this section were specifically taken from the work by Tjin et al.14. In this work, three aECM proteins were successfully cloned into the pET22b(+) expression vector. Sequential ligation first began with ligating the elastin repeats insert into the pET vector, followed by inserting the cell binding domain. Finally the last set of elastin repeats were inserted at the terminal end of the cell binding domain by using the same method. To verify if the recombinant genes has been successfully constructed, each recombinant plasmid was test digested with XhoI and SalI for 3 hr at 37 °C. Figure 1 shows the DNA insert and vector bands after the test digestion. For each of the aECM proteins, the size of the inserts corresponded to the size of the gene, confirming that the cloning was indeed successful. Further verification through DNA sequencing also confirmed the test digestion results.
We were able to purify the aECM proteins through ITC given sufficient elastin content present in each aECM protein. Figure 2 shows the schematic of the overall purification process. The O/N culture was inoculated in 1 L shake flask with a typical starting OD600 of 0.01. The culture grew to OD600 of 0.6-0.8 after 3-4 hr. Protein expression was induced using 1 mM of IPTG. After 4 hr, the typical OD of 1.5 is achieved. The bacterial culture was harvested and subjected to centrifugation. The supernatant was discarded and the cell pellet was weighed. The average weight of the cell pellet was about 3 g/L of culture. The pellet was re-suspended in TEN buffer and frozen at -80 °C O/N.
A series of freeze/thaw cycles were used to lyse the cells. The freeze-thaw step causes the cell to swell and shrink, ultimately breaking due to ice crystals formed during the freezing process. Subsequently, DNase I and RNase I were added to the cell lysate to digest all DNA and RNA. PMSF is a protease inhibitor, which was also added to the cell lysate to minimize protein degradation. To further ensure complete cell lysis, the lysate was further sonicated while kept on ice.
The cell lysate was then subjected to 3 cycles of ITC purification. At the end of the 3 cycles, the pellet at the end of the warm cycle resembled honey in consistency and had a slight yellow coloration. The pellet turned transparent upon contact with water, and readily dissolved in pre-chilled autoclaved water with shaking. The purified protein is dialyzed to remove any residual salt. The protein solution obtained at the end of the final warm cycle was transferred to a short length of dialysis tubing (with 12 kDa molecular weight cut off). At the end of the dialysis, the protein solution was transferred to a clean 50 ml centrifuge tube and frozen at -20 °C. The next day, the frozen protein solution was lyophilized to remove the water content. Figure 3 shows an image of the dialyzed protein, having a typical wool-like appearance.
To determine if the protein expression was indeed induced, samples collected before and after induction were analyzed by SDS-PAGE electrophoresis. Here, 12% SDS-PAGE gel was sufficient to separate proteins with molecular weights of 20-150 kDa. In the event that the molecular weight is large, i.e., > 100 kDa, 8% SDS-PAGE gels could be used for better protein separation. Figure 4 shows an intense protein band at the predicted molecular weight in the induced sample (lane 2). Typically, SDS-PAGE analysis was performed immediately after protein expression before purification commences. Subsequently, samples taken through the purification process could also be analyzed using SDS-PAGE electrophoresis to ensure efficient purification of the target protein. Figure 4 also shows a SDS-PAGE gel containing a purified protein sample with a molecular weight of 22 kDa (lane 4), corresponding to the LN-5 aECM14. The estimated purity of the aECM proteins was about 90%-95%; this value was derived by comparing ratios of the band intensities of the target protein and other protein bands present on the SDS gel (Figure 4, lane 4). Finally, to determine if the purified protein was indeed the aECM proteins, western blotting was performed. Subsequently, MALDI-TOF was also performed to determine accurately the impurity content of the purified material14. Figure 5 shows the protein purity of the three aECM proteins with a SDS-PAGE gel in Figure 5A and to compare against an image of the nitrocellulose membrane for western blotting in Figure 5B, showing the presence of the target proteins Col-IV aECM and LN-5 aECM, tagged using anti-6x His-tag antibodies conjugated with Horse-radish Peroxidase (HRP). The final yields of the aECM proteins ranged between 60 mg/L to 120 mg/L.
Figure 1. DNA agarose gel electrophoresis of aECM proteins. Verification of final aECM protein DNA constructs through restriction enzymes digestion ran on 1.2% DNA agarose gel. Recombinant plasmids encoding for each of the aECM proteins were double digested with XhoI and SalI for 3 hr at 37 °C. The sizes of the inserts correspond to the size of each aECM protein gene (FN910: 1.8 kbp, Col-IV: 696 bp, LN-5: 699 bp) and the size of the vector pET22b(+) used is 5.5 kbp.
Figure 2. Schematic flow for the protein expression, lysis and purification of aECM proteins. The basic guide for recombinant protein expression, starting from the inoculation of a single colony to small culture and scale up to 1 L culture, harvesting and resuspending of cells, followed by protein lysis. Protein purification was carried out by using LCST behavior of elastin-like domains present in the artificial ECM proteins. The aECM proteins are purified via ITC. Multiple cold and warm cycles were performed to achieve a high purity of target protein. Finally, the target protein were dialyzed with water and lyophilized until further use. “O/N” = overnight. “s/n” = supernatant.
Figure 3. Image of lyophilized aECM protein purified by Inverse Transition Cycling. Lyophilized LN5-aECM has a wool-like appearance.
Figure 4. SDS-PAGE gel electrophoresis of aECM protein (LN-5 aECM). Lane 1 and 2 shows culture before and after protein induction. Presence of a thick band near 22 kDa shows that the LN-5 aECM was successfully expressed. Lane 3 shows the full cell lysate while lane 4 shows the purified LN-5 aECM protein after 3 cycles of ITC.
Figure 5. (A) SDS-PAGE gel of the aECM proteins. (B) Western blot probed for 6x His-tag for Col-IV and LN-5 aECM proteins. Both Col-IV and LN-5 aECM proteins contain C-terminus 6xHis-tag. Positive chemiluminescence observed at the predicted molecular weight at 22 kDa for sample LN-5 aECM and 24 kDa for sample Col-IV aECM representing 6x His-tag present in the purified protein.
Media / L | Components and instructions |
SOC media | 20 g Tryptone |
5 g Yeast extract | |
0.6 g NaCl | |
0.2 g KCl | |
Add and autoclave in 940 ml water, | |
then add sterile (filter sterilized) | |
10 ml 1 M MgCl2 | |
10 ml 1 M MgSO4 | |
40 ml 20% glucose | |
2xYT media | 16 g Tryptone |
10 g Yeast extract | |
5 g NaCl | |
15 g Bacto Agar (addition only for agar plate) | |
Dissolve in water and top up to 1 L and autoclave. | |
To prepare agar plates, cool to 55 °C before the addition of antibiotics. | |
Mix well prior to pouring in Petri dish. | |
Cool the plates until agar is solidified. | |
Wrap plates in Parafilm and store upside-down in 4 °C. | |
Terrific Broth (TB) | 12 g Tryptone |
24 g Yeast extract | |
4 ml Glycerol | |
Dissolve in 700 ml water and autoclave. | |
16.42 g K2HPO4 (Merck) | |
2.31 g KH2PO4 (Merck) | |
Dissolve in 300 ml water and autoclave separately, to ensure salts are fully dissolved. | |
Combine both medium and salts after cooling. |
Table 1. Recipes for SOC media, 2xYT media/agar and Terrific Broth. Media for E. coli culture used in molecular cloning and protein expression.
Solution / L | Components and instructions |
Coomassie Brilliant Blue stain | 0.25 g Coomassie blueR250 |
100 ml Glacial acetic acid | |
450 ml Methyl alcohol | |
450 ml water | |
Destaining solution | 100 ml Glacial acetic acid |
400 ml Methyl alcohol | |
500 ml water |
Table 2. Recipes for solutions to stain and destain SDS-PAGE gel. Coomassie Brilliant Blue R250 for staining and a destaining solution for characterization using SDS-PAGE.
Recombinant protein engineering is a versatile technique to create novel protein materials using a bottom-up approach. The protein-based materials can be designed to have multiple functionalities, tailored according to the application of interest. Due to increasing advancement in cloning and protein expression technologies, it has become relatively simple (and cost effective) to create a variety of artificial proteins in a reproducible and scalable manner. The elastin-like domain has been incorporated in a number of artificial proteins, to serve as a purification tag, as well as to confer mechanical properties. Artificial proteins that contain an elastin-like sequence can be readily purified using ITC, which eliminates the need for expensive purification columns and antibodies.
This protocol describes the steps to construct recombinant plasmids encoding for aECM proteins. Genes encoding for the elastin-like repeats were purchased. For highly repetitive peptide sequence like elastin like polypeptides, it is recommended to design the cloning strategy such that recursive directional ligation (RDL) strategies can be used22. By using RDL, repetitive polypeptides with a specific chain length could be synthesized and therefore genes of interest can be purchased as short monomers.
In our work, the cell-binding domains were designed to contain flanking NheI restriction sites on both ends to allow modular swapping of the central cell binding domain. It is important to select restriction sites that are unique and are not present in the functional domain or elsewhere outside of the multiple cloning site (MCS) of the host vector. This is to confine the digestion of the insert or vector to the intended sites. In some cases, it may be necessary to introduce new restriction sites in the host vector using mutagenesis prior to insertion of the functional domain.
Our cloning strategy allowed us to readily change the central cell binding domain to obtain three variants of aECM proteins. We also noted that inserting a lysine residue after the starting Methionine increased protein yield by more than 10-fold. This dramatic increase in protein yield was most apparent with LN-5 aECM protein, where the final protein yield increased from 5 mg/L to 60 mg/L.
Various E. coli expression hosts were compared, and the BL21(DE3)pLysS E. coli strain gave the best protein yields. The improvement in protein yield was minimal when protein expression was induced with IPTG for longer than 4 hr. There was no significant difference in protein expression at IPTG concentrations greater than 1 mM. However, protein expression was the highest when induced at O.D. closer to 0.6.
For effective recovery of aECM proteins using ITC, it is important to note the temperature of the centrifuge apparatus. For example, most of the purification steps were performed in a cold room (4 °C) to ensure maximal solubility of the aECM proteins. It may also be necessary to pre-chill to (4 °C) the centrifuge rotor O/N prior to the cold cycle. Likewise, the centrifuge rotor was pre-heated to (37 °C) prior to the warm cycle to ensure that the temperature of the protein solution was maintained above its Tt.
In summary, the procedures to design and clone recombinant plasmids encoding artificial ECM proteins are described. In particular, the expression and purification of the aECM proteins using ITC are outlined. Finally, characterization of the aECM proteins using SDS-PAGE electrophoresis and Western Blotting were described.
The authors declare that they have no competing financial interests.
The authors would like to acknowledge funding from Ministry of Education AcRF Tier 1 (RG41) and start up grant from Nanyang Technological University. Low and Tjin are funded by the Research Student Scholarship (RSS) from Nanyang Technological University, Singapore.
Name | Company | Catalog Number | Comments |
pET22b (+) | Novagen | 69744 | T7 expression vectors with resistance to ampicillin |
BL21(DE3)pLysS | Invitrogen | C6060-03 | additional antibiotics - chloramphenicol |
Isopropyl-beta-D-thiogalactoside (IPTG) | Gold Biotechnology | I2481C | 1M stock solution with autoclaved water, make fresh prior to induction. |
QIAprep Spin Miniprep Kit | Qiagen | 27106 | plasmid isolation kit |
T4 ligase | New England Biolabs | M0202S | |
Ampicillin | Affymetrix | 11259 | |
Chloramphenicol | Affymetrix | 23660 | |
Zymoclean™ gel DNA recovery kit | Zymo Research | D4001 | |
XL10-gold strain | Agilent Technologies | 200315 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved